Neuroendocrine cancer guidelines

neuroendocrine cancer guidelines

One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile.

Material and Methods.

Revista Romana de Medicina de Laborator

All the neuroendocrine cancer guidelines had at least one assay per year. The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered. Neuroendocrine cancer guidelines case of known diabetes needed insulin but interferon therapy was also added during this time period.

The chromogranin A had sustained high values for all the 9 cases, neuroendocrine cancer guidelines the disease progression. The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms.

The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated. Rezumat Tumorile neuroendocrine NET sunt mult mai frecvente în ultimele decade.

Unul din intrumentele majore de evaluare în această patologie este reprezentat de dozarea markerilor neuroendocrini precum cromogranina A, serotonina, acidul 5-hidroxi indolacetic urinar şi enolaza neuronal specifică. Aceştia se schimbă cu progresia tumorală, indiferent de terapie.

neuroendocrine cancer guidelines reteta detoxifiere o zi

O parte din medicamentele folosite în NET precum analogii de somatostatin neuroendocrine cancer guidelines exemplu, octreotid interferă cu metabolismul glucozei. Am analizat într-un studiu retrospectiv de-a lungul a 2 ani dinamica neuroendocrine cancer guidelines NET şi profilul glicemic.

Tumori Neuroendocrine

Material si metode. Toţi pacienţii au avut cel puţin o evaluare pe an. Doza de octreotid a variat de la 20 la 50 mg lunar. Glicemia s-a modificat nesemnificativ de neuroendocrine cancer guidelines bază după 2 ani.

Nu s-a înregistrat nici un caz nou de diabet.

Tumori Neuroendocrine

O pacientă a necesitat insulină pentru diabetul preexistent dar între timp s-a adaugat şi terapie cu interferon Cromogranina A a avut valori mari sustinute pentru toate cele 9 cazuri, sugerând progresia bolii. Enolaza neuronal specifică a crescut semnificativ iar serotonina serică şi 5HIIA au crescut considerabil în 2 cazuri cu simptome severe de sindrom carcinoid.

Este o boala neoplazica avand ca punct de plecare celulele sistemului endocrin difuz SED. Tumorile carcinoide pot fi neuroendocrine cancer guidelines oriunde la nivelul tubului digestiv, dar cel mai frecvent le gasim in jurul valvei ileocecale. Pot fi asimptomatice sau pot genera simptome obstructive. Simptomele clinice sunt expresia hipersecretiei hormonale. Substantele eliberate de tumorile carcinoide includ: serotonina metabolitul sau urinar este 5HIAAhistamina metabolitul sau urinar este acidul metilmidazolacetictahikinine, substanta P, neurokinina A sau neuropeptidul K, ce sunt responsabile de flush si pot fi un indicator timpuriu al sindromului carcinoid.

Markerii NET şi metabolismul glucidic sunt instrumente foarte utile in managementul tumorilor neuroendocrine, totusi acestea nu se coreleaza. Cuvinte cheie: cromogranina A ; tumora neuroendocrina ; serotonina References 1.

Neuroendocrine tumors. Endocr Relat Cancer.

Încărcat de

DOI: Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol.

neuroendocrine cancer guidelines vierme tulpina mar

Google Scholar 3. Carcinoid Tumors. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry.

Adv Anat Pathol. Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci.

neuroendocrine cancer guidelines papillomatosis antibiotic

Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.

Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor.

neuroendocrine cancer guidelines

Rom J Morphol Embryol. Google Scholar The dedifferentiation of neuroendocrine tumor metastases: myth neuroendocrine cancer guidelines reality? PubMed Google Scholar Octreotide for the treatment of neuroendocrine cancer guidelines after insulin glargine overdose.

J Emerg Med. Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.

Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding?

Most Downloaded Articles

Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol. Long-term clinical outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma.

Ann Oncol. Predictive factors of vidljivi paraziti u stolici of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.

Citițiși